RFK Jr.'s HHS Nomination Shakes Markets and Sparks Controversy

Vaccine and pharmaceutical stocks fell sharply after Donald Trump nominated vaccine skeptic Robert F. Kennedy Jr. as the head of the US Department of Health and Human Services. Kennedy's controversial views on vaccines and the FDA have raised concerns about potential policy changes, impacting companies like Moderna, Pfizer, GSK, and Sanofi. The nomination is expected to face a challenging Senate confirmation process. Despite the market reaction, some industry insiders believe Kennedy's ideas are unlikely to become policy.